Lorna Hopcroft

May 12, 2024 | nature.com | Thomas G. Hayhow |Rodrigo J. Carbajo |David Fisher |Frederick W. Goldberg |Lorna Hopcroft |Philip Hopcroft | +5 more

AbstractTargeting the estrogen receptor alpha (ERα) pathway is validated in the clinic as an effective means to treat ER+ breast cancers. Here we present the development of a VHL-targeting and orally bioavailable proteolysis-targeting chimera (PROTAC) degrader of ERα. In vitro studies with this PROTAC demonstrate excellent ERα degradation and ER antagonism in ER+ breast cancer cell lines. However, upon dosing the compound in vivo we observe an in vitro-in vivo disconnect.

Aug 18, 2023 | nature.com | Lorna Hopcroft |Stuart Williamson |Susana Ros |Larissa S. Carnevalli |Elza DeBruin

Correction to: npj Breast Cancer https://doi.org/10.1038/s41523-023-00571-w, published online 05 August 2023In this article the author name Scott Hoffmann, was incorrectly written as Scott Hoffman. The original article has been corrected.

Aug 5, 2023 | nature.com | Stuart Williamson |Susana Ros |Lorna Hopcroft |Larissa S. Carnevalli |Elza DeBruin

Cell culture and reagentsAll cell lines were authenticated using DNA fingerprinting short-tandem repeat (STR) assays. To generate resistant cell populations, parental cell lines were exposed to escalating concentrations of palbociclib over 4–6 months. T47D cells were cultured up to a final dose of 3 μM, which generated two PalboR cell pools (named T47D RB− & T47D CDK6H).